Biothera Inc., of Eagen, Minn., said it completed enrollment of its 90-patient Phase IIb study testing Imprime PGG, Avastin (bevacizumab, Roche AG) and two chemotherapeutic drugs in non-small-cell lung cancer

The open-label trial is comparing Treakisym and Rituxan (rituximab, Biogen Idec Inc. and Roche AG) to R-CHOP

Mundipharma International Corp., of Cambridge, UK, said results from the StiL NHL-1 study published in The Lancet showed that a first-line treatment regimen of bendamustine plus Rituxan (rituximab, Biogen Idec Inc. and Roche AG) doubled progression-free survival compared with CHOP plus rituximab in newly diagnosed patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma (69.5 months vs. 31.2 months; p < 0.0001

The protocol has been expanded to enroll up to 25 additional patients at the 900-mg dose level in the Phase I/II trial evaluating the safety, tolerability and efficacy of ublituximab, the company's third-generation anti-CD20 monoclonal antibody, for patients with rituximab (Rituxan, Biogen Idec Inc. and Roche AG) relapsed or refractory B-cell non-Hodgkin's lymphoma

Circadian Technologies Ltd., of Melbourne, Australia, reported that more than 30 patients have received weekly doses of VGX-100 (human anti-VEGF-C antibody) at doses ranging from 1 to 20 mg/kg in a Phase I trial of the compound with or without bevacizumab (Avastin, Roche AG

Adherex Technologies Inc., of Research Triangle Park, N.C., said it completed patient enrollment in its Phase II study testing the oral regimen of eniluracil plus 5-fluorouracil (5-FU) and leucovorin vs. Xeloda (capecitabine, Roche AG) in metastatic breast cancer

Additional data were presented from studies testing consolidation therapy with Zevalin in patients 65 and older with CD20-positive non-Hodgkin's lymphoma and testing a short course of Treanda (bendamustine, Teva Pharmaceuticals Industries Ltd.) and Rituxan (rituximab, Biogen Idec Inc. and Roche AG) followed by Zevalin in patients with chemotherapy-naïve follicular lymphoma

The second Phase III trial resulted in a median two-year progression-free survival rate of 92 percent in patients with diffuse large B-cell lymphoma who received maintenance lenalidomide, compared with 83 percent for patients receiving lenalidomide plus Rituxan (rituximab, Biogen Idec Inc. and Roche AG

The data suggested VAL-083 is differentiated from standard of care and demonstrated the drug's potential as a future treatment option for patients with glioblastoma multiforme who have failed front-line therapy with Temodar (temozolomide, Merck & Co. Inc.) and have failed or are ineligible for second-line Avastin (bevacizumab, Roche AG/Genentech Inc

Emergent BioSolutions Inc., of Rockville, Md., said it started a Phase Ib study of TRU-016 in combination with Rituxan (rituximab, Biogen Idec Inc. and Roche AG) in patients with previously untreated chronic myelogenous leukemia

Regeneron Pharmaceuticals Inc., of Tarrytown, N.Y., said detailed one-year results from the VIEW 1 and VIEW 2 Phase III trials published in Ophthalmology showed that Eylea (aflibercept), dosed every eight weeks following three initial monthly injections, was clinically equivalent to Lucentis (ranibizumab, Roche AG) dosed every four weeks, as measured by the primary endpoint of maintenance of best-corrected visual acuity (less than 15 letters of vision loss on an eye chart as measured on an ETDRS

Cancer Research UK, of London, reported Phase III data showing that elderly patients with advanced non-small-cell lung cancer who developed a rash within 28 days of receiving targeted therapy Tarceva (erlotinib, Roche AG and Astellas Pharma Inc.) survived an average of 6.2 months, compared to 4.1 months for patients who received placebo

In the double-blind trial, Lpath plans to dose 160 subjects who have not responded completely to a VEGF inhibitor – Lucentis (ranibizumab, Roche AG) or Avastin (bevacizumab, Roche

Eli Lilly and Co., of Indianapolis, said the Phase III POINTBREAK trial did not meet its primary endpoint of improved overall survival for patients with nonsquamous non-small-cell lung cancer who were randomized to receive a combination of Alimta (pemetrexed) with Avastin (bevacizumab, Roche AG) and carboplatin induction followed by Alimta plus Avastin maintenance, compared to the combination of paclitaxel with Avastin and carboplatin followed by Avastin maintenance

TG Therapeutics Inc., of New York, said it started a Phase I/II trial of ublituximab, its third-generation anti-CD20 monoclonal antibody, in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma who previously were treated with Rituxan (rituximab, Biogen Idec Inc. and Roche AG

The company anticipates initially focusing on patients with non-small-cell lung cancer who have developed resistance to reversible tyrosine kinase inhibitors such as Tarceva (erlotinib, Roche AG and Astellas Pharma Inc.) and/or Iressa (gefitinib, AstraZeneca plc

Nektar Therapeutics Inc., of San Francisco, said an investigator-sponsored Phase II study of etirinotecan pegol in patients with bevacizumab (Avastin, Roche AG)-resistant, high-grade glioma was launched at Stanford Cancer Institute

Spectrum Pharmaceuticals Inc., of Henderson, Nev., said data published in the Journal of Clinical Oncology showed first-line consolidation with Zevalin (ibritumomab tiuxetan) injection in patients with mantle-cell lymphoma, following initial therapy consisting of Rituxan (rituximab, Biogen Idec Inc. and Roche AG) with cyclophosphamide, doxorubicin, vincristine and prednisone (RCHOP) given for four courses, was well tolerated and improved overall response rate from 68 percent after RCHOP to 82

Spectrum Pharmaceuticals Inc., of Henderson, Nev., said data published in Blood showed that the addition of Zevalin (ibritumomab tiuxetan) following fludarabine, cyclophosphamide and Rituxan (rituximab, Roche AG and Biogen Idec Inc.) conditioning and nonmyeloablative allogeneic stem cell transplantation resulted in a significantly improved six-year overall survival estimate of 80 percent in chemotherapy-refractory patients with advanced, relapsed non-Hodgkin's lymphoma